Treating recurrent tuboovarian carcinoma with multiple lines of bevacizumab-based therapy: Feasibility and effectiveness in the clinical routine.

e17541Background: Retreatment with bevacizumab (Bev) in tuboovarian carcinoma (TOC) has not been intensively investigated so far. This retrospective study sought to yield more concise data on both feasibility and effectiveness of multiple lines of Bev-based systemic treatment (Tx) in patients (pts) with recurrent TOC. Methods: A total of 90 pts with recurrent TOC who did not qualify for recruitment into a controlled trial receiving at least one line of Bev-based therapy were included. 37 (41.1%) pts had one, 20 (22.2%) had two, 13 (14.4%) had three and 20 had (22.2%) 4-9 lines of Bev. A total of 225 courses of Bev-based treatment were administered: 58 (25.8%) as monotherapy (Bev), 63 (28.0%) in combination with conventional Ctx (Bev+cCtx), and 104 (46.2%) in combination with metronomic Ctx (Bev+mCtx). Time to progression (TTP) was calculated from the start of each Bev-based Tx until progression, overall survival (OS) was calculated from the start of the first Bev-based Tx until death from any reason or lo...